Analysis of Selected Eye Disorders in a Group of Predisposed Breeds of Dogs: Molecular Diagnostics of Collie Eye Anomaly and Progressive Retinal Atrophy
Genes · 2025
DOI: 10.3390/genes16050474 ↗Kurz gefasst
Fachartikel in der Zeitschrift Genes, 2025. Verfasst von Jaroslav Bučan und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biology and Physiology, University of Veterinary Medicine and Pharmacy in Košice, Komenského 73, 04181 Košice, Slovakia. Hauptthemen laut MEDLINE: Dog Diseases, Retinal Degeneration. Die Arbeit nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Scientific Grant Agency of the Slovak Republic, Cultural and Educational Grant Agency of the Ministry of Education, Research, Development and Youth of the Slovak Republic, Cultural and Educational Grant Agency of the Ministry of Education, Research, Development, and Youth of the Slovak Republic.
Abstract (Originalsprache)
Background
Two hereditary eye disorders that are frequently observed in Collies and related breeds are Collie Eye Anomaly (CEA) and Progressive Retinal Atrophy (PRA). The main symptom of CEA is choroidal hypoplasia. It is associated with a 7.8 kb deletion in intron 4 of the NHEJ1 gene located on chromosome CFA7. Rod–cone dysplasia 3 (RCD3), an early-onset form of PRA, is associated with mutations in the PDE6A gene.
Methods
Molecular diagnostic techniques were used in this study to identify genetic mutations linked to CEA and RCD3-type PRA in a subset of dog breeds. Australian Shepherds (n = 29), Border Collies (n = 9), Longhaired Collies (n = 27), and Shetland Sheepdogs (n = 10) provided a total of 75 DNA samples. Samples were collected by buccal swab or blood draw, and PCR and real-time PCR methods were used for processing.
Results
Of the dogs in the studied breeds, 31 had the NHEJ1 gene mutation linked to CEA. Among these, 15 were homozygous recessive (affected), while 16 were heterozygous (carriers). None of the samples had any mutations in the PDE6A gene associated with RCD3-type PRA.
Conclusions
Effective identification of carriers and affected individuals for CEA was made possible by PCR-based genetic testing, confirming its value in early diagnosis and breed control. Although the RCD3 form of PRA has not been previously reported in Collies or Australian Shepherds, it was included in our analysis due to the genetic relatedness among herding breeds and the potential presence of undetected carriers resulting from historical crossbreeding.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biology and Physiology, University of Veterinary Medicine and Pharmacy in Košice, Komenského 73, 04181 Košice, Slovakia.
ORCID-Profile: Jaroslav Bučan, Jana Halušková, Viera Schwarzbacherová
Förderung
- Scientific Grant Agency of the Slovak Republic
- Cultural and Educational Grant Agency of the Ministry of Education, Research, Development and Youth of the Slovak Republic
- Cultural and Educational Grant Agency of the Ministry of Education, Research, Development, and Youth of the Slovak Republic
Zitieren
APA
Bučan, J., Holečková, B., Galdíková, M., Halušková, J., & Schwarzbacherová, V. (2025). Analysis of Selected Eye Disorders in a Group of Predisposed Breeds of Dogs: Molecular Diagnostics of Collie Eye Anomaly and Progressive Retinal Atrophy. Genes. https://doi.org/10.3390/genes16050474
Vancouver
Bučan J, Holečková B, Galdíková M, Halušková J, Schwarzbacherová V. Analysis of Selected Eye Disorders in a Group of Predisposed Breeds of Dogs: Molecular Diagnostics of Collie Eye Anomaly and Progressive Retinal Atrophy. Genes. 2025. doi:10.3390/genes16050474
BibTeX
@article{Buan2025,
author = {Bučan, Jaroslav and Holečková, Beáta and Galdíková, Martina and Halušková, Jana and Schwarzbacherová, Viera},
title = {Analysis of Selected Eye Disorders in a Group of Predisposed Breeds of Dogs: Molecular Diagnostics of Collie Eye Anomaly and Progressive Retinal Atrophy},
journal = {Genes},
year = {2025},
doi = {10.3390/genes16050474}
}
EUVIMED